UK Kidney Association Clinical Practice Guideline : Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
© 2023. BioMed Central Ltd., part of Springer Nature..
Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full "lay" summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC nephrology - 24(2023), 1 vom: 25. Okt., Seite 310 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Roddick, Alistair J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute kidney injury |
|---|
| Anmerkungen: |
Date Completed 14.11.2023 Date Revised 14.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12882-023-03339-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363728163 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363728163 | ||
| 003 | DE-627 | ||
| 005 | 20240214232854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12882-023-03339-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM363728163 | ||
| 035 | |a (NLM)37880609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Roddick, Alistair J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a UK Kidney Association Clinical Practice Guideline |b Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.11.2023 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
| 520 | |a Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full "lay" summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Acute kidney injury | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Gliflozin | |
| 650 | 4 | |a Guideline | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 700 | 1 | |a Wonnacott, Alexa |e verfasserin |4 aut | |
| 700 | 1 | |a Webb, David |e verfasserin |4 aut | |
| 700 | 1 | |a Watt, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Staplin, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Riding, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Lioudaki, Eirini |e verfasserin |4 aut | |
| 700 | 1 | |a Kuverji, Apexa |e verfasserin |4 aut | |
| 700 | 1 | |a Kossi, Mohsen El |e verfasserin |4 aut | |
| 700 | 1 | |a Holmes, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Holloway, Matt |e verfasserin |4 aut | |
| 700 | 1 | |a Fraser, Donald |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Burton, James O |e verfasserin |4 aut | |
| 700 | 1 | |a Bhandari, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Herrington, William G |e verfasserin |4 aut | |
| 700 | 1 | |a Frankel, Andrew H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC nephrology |d 2000 |g 24(2023), 1 vom: 25. Okt., Seite 310 |w (DE-627)NLM109571673 |x 1471-2369 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:1 |g day:25 |g month:10 |g pages:310 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12882-023-03339-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 1 |b 25 |c 10 |h 310 | ||